Pulmonary Drug Delivery Systems Market

The pulmonary drug delivery systems market is anticipated to grow from US$ 54.14 billion in 2024 to US$ 73.14 billion by 2031, reflecting a CAGR of 4.4% from 2025 to 2031.

Market Insights and Analyst Perspective:

Pulmonary drug delivery systems are designed to administer aerosols directly to the epithelial cells and respiratory epithelium via inhalation. These systems encompass devices like inhalers and nebulizers that deliver medications to the lungs for treating respiratory conditions. Various drug formulations and delivery mechanisms are utilized in pulmonary drug delivery devices. Key respiratory diseases necessitating these devices include asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, allergic rhinitis, and cystic fibrosis. The rising prevalence of respiratory diseases, along with strategic initiatives from companies, is driving the growth of the pulmonary drug delivery systems market. Notable trends include advancements in inhaler technologies that are expected to further boost market growth in the coming years.

Growth Catalysts:

Firms in the pulmonary drug delivery systems sector are consistently pursuing strategic initiatives such as collaborations, agreements, partnerships, and new product introductions. These strategies enhance their sales, expand their geographic presence, and improve their ability to cater to a larger customer base. New product launches are primarily aimed at enhancing safety, user-friendliness, and dosing accuracy to attract a broader patient demographic. Below are some significant developments in the pulmonary drug delivery systems market:

1. In September 2021, BreatheSuite Inc. obtained 510(K) clearances from the US FDA for its BreatheSuite metered-dose inhaler V1, intended for both prescription and over-the-counter use. This device transforms standard metered-dose inhalers into smart inhalers by automatically monitoring and providing feedback on inhaler adherence and technique for asthma and COPD patients.
2. In June 2021, Glenmark Pharmaceuticals Ltd launched Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler, in the UK for COPD treatment.
3. In April 2021, KINDEVA DRUG DELIVERY partnered with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology.
4. In December 2020, AireHealth, a digital health innovator, received 510(k) clearance for its connected nebulizer, a portable electronic vibrating mesh nebulizer designed for nebulizing liquid medications for patient inhalation, marketed as VitalMed.
5. In September 2020, GlaxoSmithKline plc and Innoviva, Inc. secured FDA approval for Trelegy Ellipta, the first once-daily single inhaler triple therapy for asthma and COPD patients aged 18 and older in the US.

Therefore, the increasing number of strategic initiatives and product launches by companies to maintain competitiveness is driving the growth of the pulmonary drug delivery systems market.

Strategic Insights

Report Segmentation and Scope:

The analysis of the pulmonary drug delivery systems market has been conducted by examining the following segments: product, indication, distribution channel, end user, and geography. The product segment includes dry powder inhalers, nebulizers, and metered dose inhalers. The indication segment is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The distribution channel segment includes hospital pharmacies, retail pharmacies, and e-commerce. The end user segment is divided into hospitals & clinics and homecare. The scope of the pulmonary drug delivery systems market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The pulmonary drug delivery systems market is categorized by product into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment accounted for a significant market share in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

By indication, the pulmonary drug delivery systems market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a notable market share in 2023 and is projected to experience the highest CAGR during 2023 to 2031.

In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment captured a significant share of the pulmonary drug delivery systems market in 2023, while the e-commerce segment is anticipated to achieve the highest CAGR from 2023 to 2031.

Regarding end user, the pulmonary drug delivery systems market is divided into hospitals & clinics and homecare. The hospitals & clinics segment held a substantial market share in 2023, whereas the homecare segment is expected to register a higher CAGR during 2023 to 2031.

Regional Analysis:

Geographically, the pulmonary drug delivery systems market is divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held a significant market share, with the US being the largest contributor in the region. The growth of the market in North America is driven by the increasing prevalence of respiratory diseases such as asthma and COPD, a growing elderly population, rising demand for diagnostic devices, and the strong presence of key market players. According to the Centers for Disease Control and Prevention (CDC) in 2020, approximately 5.0% of adults in the US are diagnosed with COPD or chronic bronchitis, with around 25 million individuals affected by asthma and 14.8 million suffering from COPD. Additionally, the Canadian Nurse Association estimates that about 3 million Canadians are afflicted with serious respiratory diseases, including COPD, cystic fibrosis, asthma, and occupational lung diseases.

The Canadian Lung Association reports that respiratory diseases account for the third highest rate of hospitalizations, with approximately one in five Canadians suffering from serious respiratory conditions such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The increasing number of patients with various respiratory diseases is driving the demand for innovative and effective pulmonary drug delivery systems, such as metered dose inhalers and nebulizers.

Pulmonary Drug Delivery Systems Market Report Scope

Industry Developments and Future Opportunities:

The pulmonary drug delivery systems market report includes an analysis of company positioning and concentration to assess the competitive landscape. Based on company press releases, here are some initiatives undertaken by key players in the market:

1. In March 2021, PARI Pharma GmbH received authorization for the LAMIRA Nebulizer System to deliver Insmed’s drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed received approval for ARIKAYCE from Japan’s Ministry of Health, Labour, and Welfare in March 2021, following earlier approvals in the US and Europe.
2. In December 2020, the European Commission approved AstraZeneca’s Trixeo Aerosphere for COPD treatment in the European Union, designed for adult patients with moderate to severe COPD. Trixeo Aerosphere is a single-inhaler, fixed-dose combination of formoterol fumarate, glycopyrronium bromide, and budesonide, delivered via a pressurized metered-dose inhaler.

Competitive Landscape and Key Players:

The forecast for the pulmonary drug delivery systems market can assist stakeholders in planning their growth strategies. Key players in the market include AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global consumer demand.

This product will be delivered within 3-5 business days.